For the quarter ending 2026-03-31, LGNDZ made $51,722K in revenue. -$13,345K in net income. Net profit margin of -25.80%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Total revenues and income | 51,722 | 23,455* | 115,461 | 47,627 |
| Cost of captisol | 3,273 | 4,487* | 3,801 | 2,907 |
| Amortization of intangibles | 8,097 | 8,176* | 8,097 | 8,258 |
| Research and development | 2,148 | 39,803* | 21,019 | 6,567 |
| Financial royalty assets impairment | - | 6,197* | 0 | 0 |
| General and administrative | 20,836 | 19,518* | 28,446 | 20,175 |
| Fair value adjustments to partner program derivatives | 0 | 665* | 833 | -1,276 |
| Total operating costs and expenses | 34,354 | 77,515* | 60,530 | 39,183 |
| Gain on sale of pelican | - | 0* | - | - |
| Operating income (gain) | 17,368 | -54,060* | 54,931 | 8,444 |
| Gain (loss) from short-term investments | 3,869 | 5,328* | 7,798 | 939 |
| Gain from change in fair value of equity-method investments and other investments | -49,229 | -23,160* | 75,887 | - |
| Interest income | 6,655 | 5,417* | 3,874 | 1,621 |
| Interest expense | 1,747 | 1,621* | 910 | 1,153 |
| Other non-operating expense, net | -1,175 | -1,482* | -443 | 1,372 |
| Total non-operating expenses, net | -41,627 | -15,519* | 86,206 | 2,779 |
| Gain before income taxes | -24,259 | -69,580* | 141,137 | 11,223 |
| Income tax benefit | -10,914 | -10,853* | 23,864 | 6,376 |
| Net income (loss) from continuing operations | - | -58,727 | - | - |
| Net gain | -13,345 | -58,727 | 117,273 | 4,847 |
| Basic EPS | -0.67 | -3.073 | 5.99 | 0.25 |
| Diluted EPS | -0.67 | -2.889 | 5.68 | 0.24 |
| Basic Average Shares | 19,883,000 | 19,109,000 | 19,578,000 | 19,327,000 |
| Diluted Average Shares | 19,883,000 | 20,327,000 | 20,629,000 | 19,926,000 |
LIGAND PHARMACEUTICALS INC (LGNDZ)
LIGAND PHARMACEUTICALS INC (LGNDZ)